Usa covid-19 Usa

I-Mab to develop therapy for Covid-19-related cytokine storm

Reading now: 249
www.pharmaceutical-technology.com

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates I-Mab Biopharma has announced plans to develop TJM2 (TJ003234) for the treatment of cytokine storm caused due to severe and critical Covid-19 infection.

Discovered by I-Mab, TJM2 is an antibody that neutralises human granulocyte-macrophage colony-stimulating factor (GM-CSF), a cytokine associated with acute and chronic inflammation.

The development will begin after the US Food and Drug Administration (FDA) accepts the company’s investigational new drug (IND) application.

A study, initially performed in the US, will then launch in other profoundly affected countries. Cytokine storm leads to elevated circulating inflammatory cytokines levels.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA